Economic analysis of the first 20 y of universal hepatitis B vaccination program in Italy: An a posteriori evaluation and forecast of future benefits

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 5, 2013, Pages 1119-1128

  Boccalini, Sara ^a   Taddei, Cristina ^a   Ceccherini, Vega ^a   Bechini, Angela ^a   Levi, Miriam ^a   Bartolozzi, Dario ^a,b   Bonanni, Paolo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Chronic hepatitis; Cirrhosis; Cost effectiveness; HBV; Hepatitis B; Hepatocellular carcinoma; Infection; Italy; Universal immunization; Vaccine

Indexed keywords

HEPATITIS B VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEALTH ECONOMICS; HEALTH PROGRAM; HEPATITIS B; HUMAN; INFANT; ITALY; MALE; NATIONAL HEALTH SERVICE; NEWBORN; PRESCHOOL CHILD; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT; VACCINATION;

CHRONIC HEPATITIS; CIRRHOSIS; COST-EFFECTIVENESS; HBV; HEPATITIS B; HEPATOCELLULAR CARCINOMA; INFECTION; ITALY; UNIVERSAL IMMUNIZATION; VACCINE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; FEMALE; HEALTH POLICY; HEALTH SERVICES RESEARCH; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; INFANT; INFANT, NEWBORN; ITALY; MALE; VACCINATION; YOUNG ADULT;

EID: 84878796280     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23827     Document Type: Article

References (34)

1. World Health Organization (WHO). Immunization surveillance, assessment and monitoring. Hepatitis B. WHO website. Available to: http://www.who.int/ immunization-monitoring/diseases/hepatitis/en/index.html
2. Romano' L, Paladini S, Van Damme P, Zanetti AR. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Dig Liver Dis 2011; 43(Suppl 1):S2-7; PMID:21195368; http://dx.doi.org/10.1016/S1590-8658(10) 60685-8.
3. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. [Review]. Vaccine 2008; 26:6266-73; PMID:18848855; http://dx.doi.org/10.1016/j.vaccine.2008.09.056.
4. Law 27 May 1991, n. 165. Obbligatorietà della vaccinazione contro l'epatite virale B. Gazz. Uff. 1° giugno 1991, n. 127.
5. Da Villa G, Sepe A. Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness. Vaccine 1999; 17:1734-8; PMID:10194831; http://dx.doi.org/10.1016/S0264-410X(98)00414-9.
6. Istituto Superiore di Sanità. Integrated Epidemiological System Of Acute Viral Hepatitis (Sistema Epidemiologico Integrato dell'Epatite Virale Acuta, SEIEVA). SEIEVA website. Available at: http://www.iss.it/seieva.
7. Crovari P, Coppola RC, Icardi GC, Bonanni P. Efficacia e sicurezza dei vaccini contro l'epatite B. In: Fondazione SmithKline, editor. La vaccinazione contro l'epatite B: una scelta prioritaria di politica sanitaria ed economica. Milano, Franco Angeli Editore; 1990. p. 59-84.
8. Dellamano R. Vaccinare contro l'epatite B: un costo senza ritorno o un buon investimento? In: Ghetti V, editor. La Vaccinazione di Massa contro l'Epatite B in Italia. Basi Fisio-patologiche, Epidemiologiche e Socioeconomiche. Milano, Franco Angeli Editore; 1991. p. 31-76.
9. Italian Ministry of Health. Hepatitis B vaccination coverage. Italian Ministry of Health website. Available to: http://www.salute.gov.it.
10. st January from 1991 to 2010, grouped by years and age range, divided by year and age. Demo.istat website. Available at: http://demo.istat.it.
11. Fattovich G. Natural history of hepatitis B. J Hepatol 2003; 39(Suppl 1):S50-8; PMID:14708678; http://dx.doi.org/10.1016/S0168-8278(03)00139-9.
12. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995; 20:992-1000; PMID:7795104; http://dx.doi.org/10.1093/clinids/20.4.992.
13. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151:599-603; PMID:3973412; http://dx.doi.org/10.1093/infdis/151.4.599.
14. Lavarini C, Farci P, Chiaberge E, Veglio V, Giacobbi D, Bedarida G, et al. IgM antibody against hepatitis B core antigen (IgM anti-HBc): diagnostic and prognostic significance in acute HBsAg positive hepatitis. Br Med J (Clin Res Ed) 1983; 287:1254-6; PMID:6416354; http://dx.doi.org/10.1136/bmj.287.6401.1254.
15. Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology 2001; 34:1225-41; PMID:11732013; http://dx.doi.org/10.1053/jhep.2001.29401.
16. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-39; PMID:17256718; http://dx.doi.org/10.1002/hep.21513.
17. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335-52; PMID:18096267; http://dx.doi.org/10.1016/j.jhep.2007.11.011.
18. Stroffolini T. The changing pattern of hepatitis B virus infection over the past three decades in Italy. Dig Liver Dis 2005; 37:622-7; PMID:15996630; http://dx.doi.org/10.1016/j.dld.2005.02.010.
19. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43(Suppl 1):S173-81; PMID:16447285; http://dx.doi.org/10.1002/hep.20956.
20. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49(Suppl):S45-55; PMID:19399792; http://dx.doi.org/10.1002/hep. 22898.
21. Stroffolini T, Almasio PL, Sagnelli E, Mele A, Gaeta GB; Italian Hospitals' Collaborating Group. Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study. J Med Virol 2009; 81:1999-2006; PMID:19856477; http://dx.doi.org/10.1002/jmv.21643.
22. Idris BI, Brosa M, Richardus JH, Esteban R, Schalm SW, Buti M. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain. [Review]. Eur J Gastroenterol Hepatol 2008; 20:320-6; PMID:18334876; http://dx.doi.org/10.1097/MEG.0b013e3282f340c8.
23. Colombo GL, Gaeta GB, Viganò M, Di Matteo S. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res 2011; 3:37-46; PMID:21935331; http://dx.doi.org/10. 2147/CEOR.S16655.
24. Cucchetti A, Cescon M, Trevisani F, Morelli MC, Ercolani G, Pellegrini S, et al. What is the probability of being too old for salvage transplantation after hepatocellular carcinoma resection? Dig Liver Dis 2012; 44:523-9; PMID:22387286; http://dx.doi.org/10.1016/j.dld.2012.01.018.
25. Gentilini P, Laffi G, La Villa G, Romanelli RG, Buzzelli G, Casini-Raggi V, et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol 1997; 92:66-72; PMID:8995940.
26. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103:1630-5; PMID:1426884.
27. Santi V, Buccione D, Di Micoli A, Fatti G, Frigerio M, Farinati F, et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol 2012; 56:397-405; PMID:21756850; http://dx.doi.org/10.1016/j. jhep.2011.05.026.
28. Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P, et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a costbenefit analysis while awaiting data on sorafenib safety. Hepatology 2010; 51:165-73; PMID:19877181; http://dx.doi.org/10.1002/hep.23260.
29. Stroffolini T, Pasquini P, Mele A. HBsAg carriers among pregnant women in Italy: results from the screening during a vaccination campaign against hepatitis B. Public Health 1988; 102:329-33; PMID:3217485; http://dx.doi.org/10. 1016/S0033-3506(88)80102-1.
30. Stroffolini T, Pasquini P, Mele A. A nationwide vaccination programme in Italy against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. Vaccine 1989; 7:152-4; PMID:2526420; http://dx.doi.org/10.1016/0264-410X(89)90056-X.
31. Stroffolini T, Pasquini P. Five years of vaccination campaign against hepatitis B in Italy in infants of hepatitis B surface antigen carrier mothers. Ital J Gastroenterol 1990; 22:195-7; PMID:2131945.
32. Stroffolini T, Bianco E, Szklo A, Bernacchia R, Bove C, Colucci M, et al. Factors affecting the compliance of the antenatal hepatitis B screening programme in Italy. Vaccine 2003; 21:1246-9; PMID:12559805; http://dx.doi.org/ 10.1016/S0264-410X(02)00439-5.
33. Spada E, Tosti ME, Zuccaro O, Stroffolini T, Mele A; Collaborating Study Group. Evaluation of the compliance with the protocol for preventing perinatal hepatitis B infection in Italy. J Infect 2011; 62:165-71; PMID:21129400; http://dx.doi.org/10.1016/j.jinf.2010.11.014.
34. Filipponi F, Pisati R, Cavicchini G, Ulivieri MI, Ferrara R, Mosca F. Cost and outcome analysis and cost determinants of liver transplantation in a European National Health Service hospital. Transplantation 2003; 75:1731-6; PMID:12777864; http://dx.doi.org/10.1097/01.TP.0000063828.20960.35.